试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-04-05
A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration
编号:NCT02873351登记状态:入组前撤回企业 / 申办者:Snyder, Robert W., M.D., Ph.D., P.C.
药物 / 成分:carbidopa-levodopa 25-100 mg、placebo for carbidopa-levodopa 25-100 mg
登记的停止原因(原文):Decided to do studies in patients with AMD
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-04-05
Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)
编号:NCT03109301登记状态:入组前撤回企业 / 申办者:National Cancer Institute (NCI)
药物 / 成分:Selumetinib (AZD6244 hyd sulfate) 50mg/dose、Selumetinib (AZD6244 hyd sulfate) 25mg/m2
登记的停止原因(原文):slow accrual
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-04-03
RCT of Goal-directed Iron Supplementation of Anemic, Critically Ill Trauma Patients, With and Without Oxandrolone
编号:NCT02047552登记状态:入组前撤回企业 / 申办者:Denver Health and Hospital Authority
药物 / 成分:Iron sucrose、Oxandrolone、IV iron placebo、Oxandrolone placebo
登记的停止原因(原文):No Participants enrolled
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-04-03
Effects of 3% Sodium Chloride on Post-operative Dysphagia Following Anterior Cervical Spine Surgery
编号:NCT03677310登记状态:入组前撤回企业 / 申办者:University of Missouri-Columbia
药物 / 成分:3% Sodium Chloride、Normal Saline
登记的停止原因(原文):Resident physician decided not to proceed with study
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-04-01
Biomarkers in Blood Samples From Young Patients With Newly Diagnosed Brain Tumors Undergoing Standard Radiation Therapy and Chemotherapy
编号:NCT01233479登记状态:入组前撤回企业 / 申办者:Pediatric Brain Tumor Consortium
药物 / 成分:systemic chemotherapy、laboratory biomarker analysis、therapeutic surgical procedure、radiation therapy
登记的停止原因(原文):This non-therapeutic study was registered in error. The PRS team doesn't delete studies once registered, so they recommended changing the status to Withdrawn
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-04-01
Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette's Syndrome
编号:NCT01475383登记状态:入组前撤回企业 / 申办者:Pfizer
药物 / 成分:PF-03654746、Placebo、Placebo、PF-03654746
登记的停止原因(原文):See termination reason in detailed description.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-04-01
Evaluation of Bromocriptine, Metoprolol and Tamsulosin in Eyes With Non-Central DME
编号:NCT03384524登记状态:入组前撤回企业 / 申办者:Andrew Moshfeghi, MD, MBA
药物 / 成分:Bromocriptine 2.5 MG、Metoprolol 25 MG、Tamsulosin 0.4 MG、Placebo
登记的停止原因(原文):withdrawn during planning stages
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-03-29
Vancomycin Treatment in Recurrent PSC in Liver Transplant Patients
编号:NCT03046901登记状态:入组前撤回企业 / 申办者:Ochsner Health System
药物 / 成分:Vancomycin
登记的停止原因(原文):0 subjects enrolled
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-03-26
Abscopal Effect for Metastatic Non-small Cell Lung Cancer.
编号:NCT02542930登记状态:入组前撤回企业 / 申办者:Zhejiang Provincial People's Hospital
药物 / 成分:Radiotherapy、Thymalfasin
登记的停止原因(原文):No recruitment.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-03-26
Sentinel Lymph Node Identification in the Axilla of Women With Breast Cancer Using Ultrasound and Iron Injection
编号:NCT02610920登记状态:入组前撤回企业 / 申办者:Columbia University
药物 / 成分:Iron-tracer guided axillary ultrasound and biopsy、Iron tracer
登记的停止原因(原文):Unable to enroll subjects
查看官方原始记录 ↗